Home › Funds › HighVista Strategies LLC › CGEM
HighVista Strategies LLC position in CGEM
CULLINAN THERAPEUTICS INC · Health Care
HighVista Strategies LLC reported holding 173,895 shares of CGEM (CULLINAN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.7M, representing 0.70% of its reported portfolio and ranking #46 among its reported holdings. HighVista Strategies LLC has disclosed CGEM holdings in 5 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How HighVista Strategies LLC's CGEM position evolved
HighVista Strategies LLC first disclosed a stake in CGEM in Q3 2024 at 31,893 shares (US$534K). The position peaked in Q3 2026 at 173,895 shares, worth US$2.7M. Across 5 filings, HighVista Strategies LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 173,895 shares valued at US$2.7M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 31.89K | $533.89K | New |
| Q4 2024 | 31.89K | $388.46K | Hold |
| Q1 2025 | 31.89K | $241.43K | Hold |
| Q2 2025 | 31.89K | $240.15K | Hold |
| Q3 2026 | 173.90K | $2.67M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CGEM and 13F data
CGEM (CULLINAN THERAPEUTICS INC) is a Health Care company. 34 other funds we track also report a position in CGEM — the largest reported positions include MPM BioImpact LLC (US$177.2M), Lynx1 Capital Management LP (US$163.2M), BVF INC/IL (US$104.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CGEM
- MPM BioImpact LLC 9.73M sh · $177.21M · Q2 2026
- Lynx1 Capital Management LP 8.96M sh · $163.23M · Q2 2026
- BVF INC/IL 5.75M sh · $104.72M · Q2 2026
- Kynam Capital Management, LP 3.11M sh · $56.71M · Q2 2026
- RTW INVESTMENTS, LP 2.36M sh · $43.05M · Q2 2026
- Siren, L.L.C. 1.79M sh · $27.53M · Q3 2026
- Venrock Adviser, LLC 1.38M sh · $25.13M · Q2 2026
- Blue Owl Capital Holdings LP 1.40M sh · $21.49M · Q3 2026
- BOOTHBAY FUND MANAGEMENT, LLC 1.08M sh · $19.71M · Q2 2026
- Affinity Asset Advisors, LLC 875.76K sh · $15.95M · Q2 2026
- BOONE CAPITAL MANAGEMENT LLC 704.44K sh · $12.83M · Q2 2026
- Elmind Capital, LP 690.00K sh · $12.56M · Q2 2026
More on HighVista Strategies LLC
FAQ
How long has HighVista Strategies LLC held CGEM?
HighVista Strategies LLC has disclosed CGEM holdings in 5 of the last 9 reported quarters, going back to Q3 2024.
What is HighVista Strategies LLC's current position in CGEM?
As of Q3 2026, HighVista Strategies LLC holds 173.90K shares of CGEM (CULLINAN THERAPEUTICS INC), valued at $2.67M, representing 0.70% of its reported portfolio and ranking #46.
Has HighVista Strategies LLC been buying or selling CGEM?
In the latest 13F filing (Q3 2026), HighVista Strategies LLC newly opened its position in CGEM. The position peaked in Q3 2026 at 173.90K shares.
Which other funds hold CGEM?
Other major institutional holders of CGEM include MPM BioImpact LLC, Lynx1 Capital Management LP, BVF INC/IL, among 34 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.